JP2001513762A5 - - Google Patents

Download PDF

Info

Publication number
JP2001513762A5
JP2001513762A5 JP1998537055A JP53705598A JP2001513762A5 JP 2001513762 A5 JP2001513762 A5 JP 2001513762A5 JP 1998537055 A JP1998537055 A JP 1998537055A JP 53705598 A JP53705598 A JP 53705598A JP 2001513762 A5 JP2001513762 A5 JP 2001513762A5
Authority
JP
Japan
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP1998537055A
Other languages
English (en)
Japanese (ja)
Other versions
JP2001513762A (ja
JP4250769B2 (ja
Filing date
Publication date
Priority claimed from AT0033997A external-priority patent/AT406867B/de
Application filed filed Critical
Publication of JP2001513762A publication Critical patent/JP2001513762A/ja
Publication of JP2001513762A5 publication Critical patent/JP2001513762A5/ja
Application granted granted Critical
Publication of JP4250769B2 publication Critical patent/JP4250769B2/ja
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

JP53705598A 1997-02-27 1998-02-18 高度に精製されたvWFまたは因子VIII/vWF複合体を得る方法 Expired - Lifetime JP4250769B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AT0033997A AT406867B (de) 1997-02-27 1997-02-27 Verfahren zur gewinnung von hochreinem vwf oder faktor viii/vwf-komplex
AT339/97 1997-02-27
PCT/AT1998/000033 WO1998038218A1 (de) 1997-02-27 1998-02-18 VERFAHREN ZUR GEWINNUNG VON HOCHREINEM vWF ODER FACTOR VIII/vWF-KOMPLEX

Publications (3)

Publication Number Publication Date
JP2001513762A JP2001513762A (ja) 2001-09-04
JP2001513762A5 true JP2001513762A5 (enExample) 2005-10-06
JP4250769B2 JP4250769B2 (ja) 2009-04-08

Family

ID=3487975

Family Applications (1)

Application Number Title Priority Date Filing Date
JP53705598A Expired - Lifetime JP4250769B2 (ja) 1997-02-27 1998-02-18 高度に精製されたvWFまたは因子VIII/vWF複合体を得る方法

Country Status (13)

Country Link
US (1) US6579723B1 (enExample)
EP (1) EP1012191B1 (enExample)
JP (1) JP4250769B2 (enExample)
AR (2) AR010122A1 (enExample)
AT (2) AT406867B (enExample)
AU (1) AU734277B2 (enExample)
CA (1) CA2282842C (enExample)
DE (1) DE59813968D1 (enExample)
DK (1) DK1012191T3 (enExample)
ES (1) ES2285758T3 (enExample)
NO (1) NO323861B1 (enExample)
SI (1) SI1012191T1 (enExample)
WO (1) WO1998038218A1 (enExample)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6926894B2 (en) 2000-11-22 2005-08-09 Baxter Aktiengesellschaft Composition exhibiting a von willebrand factor (vWF) protease activity comprising a polypeptide chain with the amino acid sequence AAGGILHLELLV
JP3862613B2 (ja) 2002-06-05 2006-12-27 キヤノン株式会社 画像処理装置及び画像処理方法並びにコンピュータプログラム
DE10246125A1 (de) * 2002-10-01 2004-04-15 Aventis Behring Gmbh Konzentrat eines Faktor VIII:C-haltigen von-Willebrand-Faktors und das dazu gehörige Verfahren
FR2874216B1 (fr) 2004-08-16 2006-11-03 Lab Francais Du Fractionnement Procede de preparation d'un concentre de facteur von willebrand (fvw) par voie chromatographique et concentre de fvw susceptible d'etre ainsi obtenu
WO2006033854A2 (en) 2004-09-07 2006-03-30 Archemix Corp. Aptamers to von willebrand factor and their use as thrombotic disease therapeutics
WO2006029258A2 (en) * 2004-09-07 2006-03-16 Archemix Corp. Aptamer medicinal chemistry
US7566701B2 (en) * 2004-09-07 2009-07-28 Archemix Corp. Aptamers to von Willebrand Factor and their use as thrombotic disease therapeutics
US7645860B2 (en) 2006-03-31 2010-01-12 Baxter Healthcare S.A. Factor VIII polymer conjugates
WO2008150495A2 (en) * 2007-06-01 2008-12-11 Archemix Corp. Vwf aptamer formulations and methods for use
FR2920429B1 (fr) * 2007-08-30 2012-10-05 Lfb Biotechnologies Procede de purification du facteur viii et du facteur von willebrand
US11197916B2 (en) * 2007-12-28 2021-12-14 Takeda Pharmaceutical Company Limited Lyophilized recombinant VWF formulations
PT2242479E (pt) * 2007-12-28 2011-11-25 Baxter Int Filtração de proteínas por contrapressão
IT1396528B1 (it) 2009-01-19 2012-12-14 Kedrion Spa Nuovo processo di purificazione altamente selettivo di due proteine plasmatiche: von willebrand factor (vwf) e fibronectina (fn).
RU2579977C2 (ru) 2009-11-13 2016-04-10 Грифольс Терапьютикс Инк. СОДЕРЖАЩИЕ ФАКТОР ФОН ВИЛЛЕБРАНДА (vWF) ПРЕПАРАТЫ И СПОСОБЫ, НАБОРЫ И ПРИМЕНЕНИЯ, СВЯЗАННЫЕ С НИМИ
AU2011343813B2 (en) 2010-12-15 2015-05-21 Takeda Pharmaceutical Company Limited Eluate collection using conductivity gradient
JP6236948B2 (ja) * 2013-07-17 2017-11-29 東ソー株式会社 抗体精製用溶出液および当該溶出液を用いた抗体精製方法
EP3205665A1 (en) * 2016-02-11 2017-08-16 Octapharma AG Method of separating factor viii from blood products
SG11202009213TA (en) 2018-03-21 2020-10-29 Baxalta Inc Separation of vwf and vwf propeptide by chromatographic methods

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0081482A1 (en) 1981-06-18 1983-06-22 E. G. Birger Blombäck A process in purification and concentration of the factor viii complex
US4361509A (en) * 1981-12-14 1982-11-30 Scripps Clinic And Research Foundation Ultrapurification of factor VIII using monoclonal antibodies
FR2570276B1 (fr) 1984-09-18 1987-09-04 Immunotech Sa Procede d'obtention du complexe fviii/vwf a usage therapeutique et produits en resultant
US5200510A (en) * 1987-06-16 1993-04-06 Zymogenetics, Inc. Method for purifying factor viii:c, von willebrand factor and complexes thereof
US4774323A (en) * 1987-06-29 1988-09-27 Rorer Pharmaceutical Corporation Purification of von Willebrand Factor solutions using gel permeation chromatography
US5006642A (en) 1987-06-29 1991-04-09 Rhone-Poulenc Rorer Pharmaceuticals Inc. Purification of von Willebrand Factor by affinity chromatography
DE3904354A1 (de) 1989-02-14 1990-08-16 Behringwerke Ag Pasteurisiertes, gereinigtes von willebrand-faktor-konzentrat und verfahren zu seiner herstellung
FR2665449B1 (fr) 1990-08-02 1995-04-14 Aquitaine Developp Transf Sang Procede de fabrication de facteur von willebrand ayant une tres haute purete, depourvu en majeure partie de facteur antihemophilique (fviiic), et facteur von willebrand ainsi obtenu, ainsi qu'une composition pharmaceutique le contenant.
FR2662166A1 (fr) * 1990-05-18 1991-11-22 Fondation Nale Transfusion San Procede de preparation de facteur viii de tres haute purete comprenant une etape rapide d'immunoadsorption.
EP0638091B1 (en) 1992-04-30 2005-12-07 Probitas Pharma Inc. Improved solubilization and stabilization of factor viii complex
IT1256622B (it) 1992-12-04 1995-12-12 Sclavo Spa Processo per l'estrazione del complesso fattore viii-fattore von willebrand (fviii:c-fvw) da plasma umano totale.
DE4435392B4 (de) 1994-10-04 2008-02-07 Immuno Ag Verfahren zur Trennung von vWF in hochmolekularen vWF und niedermolekularen vWF
DE4435485C1 (de) 1994-10-04 1996-03-21 Immuno Ag Verfahren zur Gewinnung von hochreinem von Willebrand-Faktor
AT403764B (de) * 1996-03-15 1998-05-25 Immuno Ag Stabiler faktor viii/vwf-komplex
CA2251558C (en) 1996-04-12 2005-11-22 Immuno Aktiengesellschaft Highly purified factor viii complex
AT403765B (de) * 1996-04-12 1998-05-25 Immuno Ag Verfahren zur herstellung einer präparation enthaltend einen hochgereinigten komplex

Similar Documents

Publication Publication Date Title
JP2000509942A5 (enExample)
JP2000509635A5 (enExample)
JP2000507042A5 (enExample)
JP2000510751A5 (enExample)
JP2000509912A5 (enExample)
JP2000509637A5 (enExample)
JP2000509587A5 (enExample)
JP2000507369A5 (enExample)
JP2000508866A5 (enExample)
JP2000508022A5 (enExample)
JP2000508841A5 (enExample)
JP2000508680A5 (enExample)
JP2000509804A5 (enExample)
JP2000509853A5 (enExample)
JP2000509755A5 (enExample)
JP2000510247A5 (enExample)
JP2000508102A5 (enExample)
JP2000508836A5 (enExample)
JP2000509818A5 (enExample)
JP2000509520A5 (enExample)
JP2000507434A5 (enExample)
JP2001513762A5 (enExample)
JP2001514655A5 (enExample)
JP2000508880A5 (enExample)
JP2001519047A5 (enExample)